![]() Three-hundreds and five patients out of 500 were randomized to receive pembrolizumab (n=154) or platinum-based chemotherapy (n=151). ![]() In the first-line setting, the open-label, randomized, phase III KEYNOTE-024 trial, showed that pembrolizumab was more effective if compared with platinum-based chemotherapy in NSCLC patients with high levels of PD-L1 expression ( 6).įive hundred (30.2%) out of tumor samples from 1,653 patients were strongly positive for PD-L1 expression (TPS ≥50%). Studies have demonstrated superior overall survival (OS) for monoclonal antibody therapy, directed against either the PD-1 receptor or its ligand, when compared with docetaxel chemotherapy. In the last 2 years the therapeutic landscape of non-small cell lung cancer (NSCLC) has seen a rapid shift with the introduction of immunotherapy into treatment strategy. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Email: This is an invited Editorial commissioned by the Section Editor Chunlin Ou (Cancer Research Institute of Central South University, Changsha, China).Ĭomment on: Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. ![]() Clinica Oncologica, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy. Interviews with Outstanding Guest EditorsĬorrespondence to: Rossana Berardi.Policy of Dealing with Allegations of Research Misconduct.Policy of Screening for Plagiarism Process.
0 Comments
Leave a Reply. |